PDS Biotechnology (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company’s proprietary Versamune(R) T-cell activating technology, on Thursday released a white paper detailing how the Versamune(R) platform works to treat cancer, and the potential of Versamune(R) in the treatment of a broad range of cancers. The current PDS Biotech pipeline of Versamune(R)-based therapies focuses on four key antigens associated with a broad variety of solid tumors that remain challenging to treat. According to PDS Biotech CEO, Dr. Frank Bedu-Addo, “We are currently pursuing an ambitious development strategy, working with leading oncology experts to assess the potential of Versamune(R) to bring new and improved treatments to cancer patients.”
To view the full press release, visit https://ibn.fm/WlZWR
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune(R) T-cell activating technology platform. Versamune(R) effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune(R) and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.PDSBiotech.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.